Your AI-Trained Oncology Knowledge Connection!

Jyoti D. Patel, MD

Articles

NSCLC: Factors in Selecting 2L Therapy After Progression on 1L ALK TKI

Stephen Liu, MD;Jyoti D. Patel, MD;D. Ross Camidge, MD, PhD;Jillian E. Thompson, NP

April 7th 2023

Expert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.

Case 2: Sequencing ALK TKIs in NSCLC

Stephen Liu, MD;Jyoti D. Patel, MD;D. Ross Camidge, MD, PhD;Jillian E. Thompson, NP

April 7th 2023

Moving on to discuss the second patient case of ALK+ NSCLC, expert panelists elucidate the sequencing ALK TKIs following progression on first-line therapy.

Frontline ALK TKIs in Patients With NSCLC: Treatment Selection and AE Management

Stephen Liu, MD;Jyoti D. Patel, MD;D. Ross Camidge, MD, PhD;Jillian E. Thompson, NP

March 31st 2023

Following their review of clinical trial data behind frontline ALK TKIs in NSCLC, key opinion leaders share practical insight on selection and use of these agents.

Frontline ALK TKIs in NSCLC: The CROWN Trial

Stephen Liu, MD;Jyoti D. Patel, MD;D. Ross Camidge, MD, PhD;Jillian E. Thompson, NP

March 31st 2023

Focusing on the CROWN clinical trial in ALK+ NSCLC, expert panelists consider the role of frontline lorlatinib therapy in this setting.

Frontline ALK TKIs in NSCLC: The ALTA-1L Trial

Stephen Liu, MD;Jyoti D. Patel, MD;D. Ross Camidge, MD, PhD;Jillian E. Thompson, NP

March 24th 2023

Shared perspectives on the frontline use of brigatinib therapy in ALK+ NSCLC and results from the ALTA-1L clinical trial.

Frontline ALK TKIs in NSCLC: The ALEX Study

Stephen Liu, MD;Jyoti D. Patel, MD;D. Ross Camidge, MD, PhD;Jillian E. Thompson, NP

March 24th 2023

Centering discussion on clinical trial data in ALK+ NSCLC, panelists highlight the frontline use of alectinib in the ALEX study.

Case 1: Frontline Treatment of ALK+ NSCLC With Brain Metastases

Stephen Liu, MD;Jyoti D. Patel, MD;D. Ross Camidge, MD, PhD;Jillian E. Thompson, NP

March 10th 2023

Shared insight on a patient case of ALK+ non–small cell lung cancer with CNS metastasis and the role of brain MRIs in clinical practice.

Overview on ALK+ Metastatic Non–Small Cell Lung Cancer

Stephen Liu, MD;Jyoti D. Patel, MD;D. Ross Camidge, MD, PhD;Jillian E. Thompson, NP

March 10th 2023

Expert panelists open their discussion on ALK+ non–small cell lung cancer and reflect on the impact of CNS metastasis in this setting.

Cediranib Versus Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer

Jyoti D. Patel, MD

September 25th 2014

Jyoti D. Patel, MD, discusses a phase II trial that looked at olaparib in combination with cediranib versus olaparib alone in recurrent platinum-sensitive ovarian cancer.

Early Treatment With Docetaxel for Metastatic Prostate Cancer

Jyoti D. Patel, MD

July 24th 2014

Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the early treatment of patients with metastatic prostate cancer.